RE: Strategy Emerging22 Mar 2023 16:18
RMM - thanks as always! I’m intrigued by the response to the question about the 1802 translational, toxicology and manufacturing studies and the confirmation by JR that the tox and manufacturing studies have not commenced. Given that the 1802 formulation has been determined, and the translational studies have been in train since Q4 2021, would it not be appropriate to run the tox and manufacturing studies in tandem? Is this simply a funding issue or something more strategic? If not, based on the time it has taken to get 1801 to the current position, we are a number of years away from getting 1902 even close to Phase 1 trials. Whilst appreciating that the focus has been on 1801 and that the MHRA debacle will have taken up a lot of JR and TMs time, one would think there would still be capacity to progress 1802.